Corporate Profile

Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. Syndax corporate headquarters are in Waltham, MA.

View Stock
Day High
Day Low
Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

09.18.24
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure
Read More
08.14.24
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting the approval show treatment with Niktimvo resulted in durable responses across all organs studied and
Read More
08.12.24
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of patients with KMT2Ar AML and ALL (p-value = 0.0036) – – NDA filing for revumenib in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – WALTHAM, Mass. , Aug.
Read More
View More
View More

Two people smiling

Recent Events

Niktimvo™ (axatilimab-csfr) FDA Approval Conference Call

08.14.24 / 6:00 PM EDT
Learn More

Syndax Second Quarter 2024 Conference Call

08.01.24 / 4:30 PM EDT
Learn More

Goldman Sachs 45th Annual Global Healthcare Conference

06.12.24 / 8:40 AM EDT
Learn More
View More

Sign Up for Email Alerts

Sign-up to automatically receive Syndax financial information by email.
Sign up
Two people holding hands